复合花粉制剂改善CCl_4诱导肝硬化大鼠血浆氨基酸失衡

目的观察复合花粉制剂对CCl4诱导的肝硬化模型大鼠的血浆氨基酸浓度的影响。方法将45只SD大鼠采用抽签法随机分为模型组(35只)和对照组(10只)。对照组与模型组动物给予同样的基础饮食;模型组按照每100 g体质量0.2 mL的剂量,腹腔注射40%CCl4葵花籽油溶液,每周2次,持续12周,待病理证实肝硬化形成,停止注射CCl4。12周时32只大鼠造模成功,对照组大鼠全部存活,营养素干预前处死模型组大鼠4只,对照组大鼠3只,检测基线血浆氨基酸浓度;余7只对照大鼠分别于营养素干预2周、4周后处死;余28只模型组大鼠随机分为组1(模型对照组)、组2(复合花粉营养素)、组3(高剂量Noveliver营养素)、组4(低剂量Noveliver营养素),分别于营养素干预2、4周后处死,检测各组干预后2、4周血浆氨基酸浓度。结果①基线血浆氨基酸浓度:模型组血浆支链氨基酸及芳香族氨基酸浓度均低于对照组,但2组支链/芳香族氨基酸比值差异无统计学意义(分别为1.48±0.05和1.48±0.13)。②营养素干预2周后血浆支链氨基酸:组3高于组4和组2;芳香族氨基酸:组2和组3低于其余3组;支链/芳香族氨基酸比值:对照组、组1、2、3、4分别为1.54±0.11、1.59±0.43、1.82±0.11、1.98±0.55和1.58±0.04,组3和组2明显高于其余3组。③营养素干预4周后血浆支链氨基酸:3组营养干预组(组2、3、4)均高于模型对照组(组1),其中组3高于组4;芳香族氨基酸:组2和组4低于其余3组;支链/芳香族氨基酸比值:正常对照组、组1、2、3、4分别为1.44±0.14、1.16±0.35、1.40±0.24、1.51±0.08和1.40±0.15,3组营养干预组(组2、3、4)均高于模型对照组(组1),其中组3高于组4。结论 CCl4所致肝硬化大鼠血浆氨基酸整体水平低于正常对照组大鼠;复合花粉制剂营养素干预有提高血浆支链氨基酸水平和支链/芳香族氨基酸比值的趋势,且高剂量Noveliver效果优于低剂量Noveliver,干预4周时效果优于2周时的结果。本实验提示复合花粉制剂有一定改善肝硬化大鼠血浆氨基酸失衡的作用。本研究为临床肝硬化患者氨基酸失衡的治疗提供了参考。

Plasma amino acids in CCl4 induced cirrhosis in rats intervened by compound pollen nutrients

Objective To observe the changes of plasma amino acids in CCl₄ induced cirrhosis in rats intervened by compound pollen nutrients. Methods Totally 45 SD rats were randomly divided into control group(n=10) and model group(n=35). The rats in the model group were given 40% CCl₄ sunflower seed oil solution(0.2 mL/100 g weight ) by intraperitoneal injection, twice per week for 12 weeks. In the 12th week, 32/35 rats in the model group were found to have liver cirrhosis confirmed by pathology, the rats in control group were all alive. Four rats in model and 3 in control group were sacrificed before the nutritional intervention and the levels of plasma amino acids were measured as baseline. The left 7 rats from control group were sacrificed at week 2 and 4 after the nutritional intervention; while the rest 28 rats in model group were randomly divided into 4 groups: Group 1(receiving normal dietary, n=7), Group 2(receiving compound pollen nutrients, n=7), Group 3(receiving high dose noveliver, n=7) and Group 4(receiving low dose noveliver, n=7). Rats of each group were sacrificed at week 2(3/7 rats) and 4(4/7 rats) respectively after the nutritional intervention and the levels of the plasma amino acids were measured for each group. Results ① The baseline levels of plasma amino acids: the levels of branched-chain amino acids(BCAA) and aromatic amino acids(AAA ) in model group were lower than in control group, the ratio of BCAA/AAA were 1.48±0.05 and 1.48±0.13 respectively with no significant difference between two groups. ② At week 2: the levels of BCAA in Group 3 was higher than in Group 2 and 4; the levels of AAA in Group 2 and 3 were lower than those of the other 3 groups; the ratios of BCAA/AAA in control group, Group 1, 2, 3 and 4 were 1.54±0.11, 1.59±0.43, 1.82±0.11, 1.98±0.55 and 1.58±0.04 respectively, the ratios of Group 2 and 3 were higher than those of the other 3 groups. ③ At week 4: the levels of BCAA of Group 2, 3 and 4 were higher than that of the normal dietary group(Group 1); the levels of AAA in Group 2 and 4 were lower than those of the other 3 groups; the ratios of BCAA/AAA in control group, Group 1, 2, 3 and 4 were 1.44±0.14, 1.16±0.35, 1.40±0.24, 1.51±0.08, and 1.40±0.15 respectively, the ratios of Group 2, 3 and 4 were higher than that of the normal dietary group(group 1). Conclusion The overall level of plasma amino acids in CCl₄ induced liver cirrhotic rats was lower than that of the rats in control group. Compound pollen nutrients tended to increase the level of plasma BCAA and the ratio of BCAA/AAA. Compared with Goup1, 2 and 4, the rats receiving high dose Noveliver(Group 3) had higher level of plasma BCAA and ratio. The intervention duration of 4 weeks achieved higher plasma BCAA level and ratio higher than that at 2 weeks. The results of the present study suggested that compound pollen nutrients may correct the imbalance of plasma amino acids in CCl₄ induced cirrhotic rats. The findings of the present study hopefully promote a better understanding of nutrient intervention in cirrhosis patients.